



350-4243 Glanford Ave.
Victoria, BC V8Z 4B9
Tel: 250-744-2811
Fax: 250-744-3331

STRESSGEN CONFERENCE CALL NOTIFICATION

Thursday, June 7, 2001 at 9:00 a.m. ET; 6:00 a.m. PT

FOR IMMEDIATE RELEASE

June 1, 2001

San Diego, California - Stressgen Biotechnologies Corporation (TSE:SSB) announced today that it will hold a conference call on Thursday, June 7 to discuss Dr. Stephen Goldstone's presentation of genital warts clinical data for HspE7 at the American Society of Colon and Rectal Surgeons (ASCRS) Annual Meeting. The ASCRS 2001 meeting will be held June 2-7 in San Diego. Dr. Goldstone's presentation is scheduled between 10:00 a.m. and 1:00 p.m. on Wednesday, June 6. Abstracts and conference proceedings for the ASCRS meeting will be available to conference registrants on June 2 through June 7.

About Conference Call

Stressgen's conference call will be held on June 7, 2001 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). The dial in number to access the call is 888-489-9485 in North America. A replay of this call will be available from June 7 at 8:00 a.m. Pacific Time through June 14, 2001. The playback number is: 800-558-5253, reservation No. 19040166. The Company will retain information about accessing the call on its website at www.stressgen.com through the playback period.

About Stressgen

Stressgen is a public biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. In addition to targeting HspE7 in HPV-related diseases, the Company has also initiated research studies to evaluate its heat shock protein technology in the treatment of bacterial diseases such as hepatitis. Stressgen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology, which are used by scientists worldwide.

Stressgen Conference Call Notification – June 1, 2001

This news release contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding the development and commercialization of therapeutics for viral infections, cancers and other diseases. Factors that may cause the ultimate results or our performance to be materially different from those implied by such forward-looking statements include risks that products are not demonstrated to be safe or effective for their intended use, that the company will not obtain approval to market its products, and that it will be difficult to progress from research to commercialization. These factors and others are more fully discussed in our filings with the U.S. Securities and Exchange Commission and Canadian regulatory authorities.

-30-

Contacts:

Donna Slade
Director, Investor Relations
4445 Eastgate Mall, 2nd Floor
San Diego, CA USA 92121
Tel: 858/812-5616
Fax: 858/812-5613
dslade@stressgen.com

Jennifer Matterson
Communications Coordinator
350-4243 Glanford Avenue
Victoria, BC CANADA V8Z 4B9
Tel: 250/744-2811
Fax: 250/744-3331
jmatterson@stressgen.com

###